Evidence map›Paper›PMID 42454476›Full record

ArticleGenetics in medicine : official journal of the American College of Medical Genetics2026

AAVC: An automated framework for high-accuracy ACMG-based variant classification.

R Arda İnan, Barış Kayaalp, Fatimah Safieh, M Ece Kars, David Stein, David N Cooper, Peter D Stenson, Özlen Konu, Jean-Laurent Casanova, Yuval Itan and 2 more

Abstract read
In one paragraph

Article in Genetics in medicine : official journal of the American College of Medical Genetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

R Arda İnanDepartment of Molecular Biology and Genetics, Faculty of Science, Bilkent University, Ankara, Türkiye.
Barış KayaalpDepartment of Molecular Biology and Genetics, Faculty of Science, Bilkent University, Ankara, Türkiye.
Fatimah SafiehDepartment of Molecular Biology and Genetics, Faculty of Science, Bilkent University, Ankara, Türkiye.
M Ece KarsThe Charles Bronfman Institute for Personalized Medicine, Icahn School of Medicine at Mount Sinai, New York, NY.
David SteinThe Charles Bronfman Institute for Personalized Medicine, Icahn School of Medicine at Mount Sinai, New York, NY; Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY; Department of Pharmacological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY.
David N CooperInstitute of Medical Genetics, School of Medicine, Cardiff University, Cardiff, United Kingdom.
Peter D StensonInstitute of Medical Genetics, School of Medicine, Cardiff University, Cardiff, United Kingdom.
Özlen KonuDepartment of Molecular Biology and Genetics, Faculty of Science, Bilkent University, Ankara, Türkiye; Neuroscience Program, Graduate School of Engineering and Science, Bilkent University, Ankara, Türkiye; Institute of Materials Science and Nanotechnology, National Nanotechnology Research Center, Bilkent University, Ankara, Türkiye.
Jean-Laurent CasanovaSt Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch, Rockefeller University, New York, NY; Laboratory of Human Genetics of Infectious Diseases, Necker Branch INSERM U1163, Necker Hospital for Sick Children, Paris, France; Imagine Institute, University of Paris, Paris, France; Pediatric Immunology-Hematology Unit, Necker Hospital for Sick Children, Paris, France; HHMI, Rockefeller University, New York, NY.
Yuval ItanThe Charles Bronfman Institute for Personalized Medicine, Icahn School of Medicine at Mount Sinai, New York, NY; Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY; Mindich Child Health and Development Institute, Icahn School of Medicine at Mount Sinai, New York, NY.
A Nazlı BaşakSuna and Inan Kıraç Foundation, Neurodegeneration Research Laboratory, Research Center for Translational Medicine, Koç University School of Medicine, Istanbul, Türkiye.
Tayfun ÖzçelikDepartment of Molecular Biology and Genetics, Faculty of Science, Bilkent University, Ankara, Türkiye; Neuroscience Program, Graduate School of Engineering and Science, Bilkent University, Ankara, Türkiye; Institute of Materials Science and Nanotechnology, National Nanotechnology Research Center, Bilkent University, Ankara, Türkiye. Electronic address: tozcelik@bilkent.edu.tr.

Funding

Developing, Demonstrating, and Disseminating Innovative Programs to Achieve Translational SuccessUL1TR001866 · NCATS · ROCKEFELLER UNIVERSITY · PI COLLER, BARRY, KRUEGER, JAMES G · 2016 to 2025
$40.6M
Yale Center for Mendelian GenomicsUM1HG006504 · NHGRI · YALE UNIVERSITY · PI GERSTEIN, MARK BENDER, GUNEL, MURAT · 2016 to 2020
$14.8M
NHGRI Genome Sequencing Program Coordinating CenterU24HG008956 · NHGRI · RUTGERS, THE STATE UNIV OF N.J. · PI BUYSKE, STEVEN G, MATISE, TARA C. · 2016 to 2020
$4.9M
Genome-wide search for inborn errors of IL-17 immunity underlying chronic mucocutaneous candidiasisR01AI127564 · NIAID · UT SOUTHWESTERN MEDICAL CENTER · PI Jean-Laurent Casanova · 2017 to 2026
$4.8M
Inborn errors of immunity in patients with life-threatening COVID-19R01AI163029 · NIAID · ROCKEFELLER UNIVERSITY · PI CASANOVA, JEAN-LAURENT, ZHANG, QIAN · 2021 to 2025
$3.7M
Genome-Wide Dissection of Mendelian Susceptibility to Mycobacterial DiseaseR01AI095983 · NIAID · ROCKEFELLER UNIVERSITY · PI BUSTAMANTE, JACINTA, CASANOVA, JEAN-LAURENT · 2021 to 2025
$2.5M
NCATS NIH HHS UL1 TR001866NHGRI NIH HHS U24 HG008956NHGRI NIH HHS UM1 HG006504NIAID NIH HHS R01 AI095983NIAID NIH HHS R01 AI127564NIAID NIH HHS R01 AI163029
6 · The paper itself

Abstract

purposeClassification of DNA sequence data requires the implementation of the American College of Medical Genetics and Genomics (ACMG) standards and guidelines. Therefore, automated tools have been developed. However, these tools often lack robust and up-to-date methodologies. This study reports on the development of a new tool and examines its performance for diagnostic and research purposes.

methodsThe automated ACMG-based variant classifier (AAVC) presented here computationally analyzes sequence variants following the ACMG guidelines, the Clinical Genome Resource specifications and a novel framework by leveraging large public databases and in silico prediction tools.

resultsAAVC demonstrated high concordance (94.39%) with the Food and Drug Administration recognized variant classifications, outperforming currently available tools. It classified 55% of the variants of uncertain significance in clinical variation into clinically significant categories. We identified, in the Turkish Variome, 215 novel pathogenic, likely pathogenic, or variants of uncertain significance high variants in the secondary finding genes and revealed that 1 in 10 individuals carried an actionable genotype.

conclusionAAVC constitutes a robust framework for the accurate classification of human germline sequence diversity is available at https://aavc.bilkent.edu.tr/, offering a highly accurate, rapid, and up-to-date platform for clinical laboratories and research groups to automatically interpret sequence variants.

Indexed as

AAVCACMGClinGenGenetic diagnosisVariant classification

Identifiers

PMID42454476
PMCPMC13374714

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.